Det vides, at CYP1A2 hæmmes af flere lægemidler, herunder fluvoxamin og omeprazol, og sådanne lægemidler kunne teoretisk påvirke anagrelid clearance negativt. • In vivo interaktionsundersøgelser hos mennesker har påvist, at digoxin og warfarin ikke påvirker anagrelids farmakokinetiske egenskaber.
It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine and omeprazole, and such medicinal products could theoretically adversely influence the clearance of anagrelide. • In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the pharmacokinetic properties of anagrelide.